

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Application No.

09/723,676

Filing Date:

11-28-2000

First Named Inventor

Welcher

Group Art Unit

1646

Examiner Name

P. J. M. M. M.

Attorney Docket No.

00,1214

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
PM		5,075,222		Hannum <i>et al.</i>	12-24-1991	
PM		5,863,769		Young	01-26-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PM		AU	9173636		Carmichael <i>et al.</i>	10-03-1991		
		DE	4219626	A1	Wehling	12-23-1993		
		EP	0 343 684	A1	Hannum <i>et al.</i>	11-29-1989		
		EP	0 855 404	A1	Young	07-29-1998		
		EP	0 879 889	A2	Young <i>et al.</i>	11-25-1998		
		WO	91/08285	A1	Hageman <i>et al.</i>	06-13-1991		
		WO	91/17184	A1	Carter	11-14-1991		
		WO	92/16221	A1	Thompson <i>et al.</i>	10-01-1992		
		WO	93/21946	A1	Russell <i>et al.</i>	11-11-1993		
		WO	94/06457	A1	Sabados	03-31-1994		
		WO	94/20517	A1	Evans <i>et al.</i>	09-15-1994		
		WO	94/21275	A1	Lefrancier <i>et al.</i>	09-29-1994		
		WO	96/22793	A1	Evans <i>et al.</i>	08-1-1996		
		WO	97/28828	A1	Collins <i>et al.</i>	08-14-1997		
		WO	97/47650	A1	Zanette <i>et al.</i>	12-19-1997		
		WO	99/06426	A1	Pan	02-11-1999		
		WO	99/35268	A1	Sims	07-15-1999		
		WO	99/36541	A1	Marshall <i>et al.</i>	07-22-1999		
		WO	99/37662	A1	Busfield	07-29-1999		
		WO	99/51744	A2	Drmanac <i>et al.</i>	10-14-1999		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED

TECH CENTER JUN 25 2001

PM	WO	00/11174	A1	Sims <i>et al.</i>	03-26-2000		
	WO	00/18800	A1	Busfield	04-03-2000		
	WO	00/20595	A1	Sheppard <i>et al.</i>	04-13-2000		
	WO	00/24899	A2	West <i>et al.</i>	05-04-2000		
	WO	00/71719	A1	Ballinger <i>et al.</i>	11-30-2000		
	WO	00/71720	A1	Sims <i>et al.</i>	11-30-2000		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PM		Nucleotide and Protein Sequences Database, EBI, UK, Accession No. AC016724. <i>1998, Sullivan et al.</i>	
		AREND <i>et al.</i> , "Interleukin-1 Receptor Antagonist: Role in Biology," <i>Annu. Rev. Immunol.</i> 16:27-55 (1988).	
		BARTON <i>et al.</i> , "A Tissue Specific IL-1 Receptor Antagonist Homolog from the IL-1 Cluster Lacks IL-ra, IL-18 and IL-18 Antagonist Activities," <i>Eur. J. Immunol.</i> 30:3299-308 (2000).	
		CARTER <i>et al.</i> , "Purification, Cloning, Expression and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein," <i>Nature</i> 344:633-38 (1990).	
		EISENBERG <i>et al.</i> , "Interleukin 1 Receptor Antagonist is a Member of the Interleukin 1 Gene Family: Evolution of a Cytokine Control Mechanism," <i>Proc. Natl. Acad. Sci. USA</i> 88:5232-36 (1991).	
		HANNUM <i>et al.</i> , "Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor," <i>Nature</i> 343:336-46 (1990).	
		KUMAR <i>et al.</i> , "Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family," <i>J. Biol. Chem.</i> 274:10308-14 (2000).	
		MULERO <i>et al.</i> , "IL1HY1: A Novel Interleukin-1 Receptor Antagonist Gene," <i>Biochem. Biophys. Res. Commun.</i> 263:702-06 (1999).	
		MULERO <i>et al.</i> , "Organization of the Human Interleukin-1 Receptor Antagonist Gene IL1HY1," <i>Immunogenetics</i> 51:425-28 (2000).	
		PAN <i>et al.</i> , "IL-1H, an Interleukin 1-Related Protein that Binds IL-18 Receptor/IL-1Rrp," <i>Cytokine</i> 13:1-7 (2001).	
		SMITH <i>et al.</i> , "Four New Members Expand the Interleukin-1 Superfamily," <i>J. Biol. Chem.</i> 275:1169-75 (2000).	

Examiner Signature	Pema Hwang	Date Considered	6/24/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231